Rituximab bio-similar for the treatment of myasthenia gravis (adults)

Document first published:: 20 April 2021
Page updated:: 23 June 2026
Topic:: Specialised commissioning
Publication type:: Policy or strategy

NHS England has concluded that there is sufficient evidence to support the routine commissioning of this treatment for patients who fulfil the criteria listed in this document.

Document

Rituximab bio-similar for the treatment of myasthenia gravis (adults)

Summary

Updated 23 June 2026.

Cookies on the NHS England website

Rituximab bio-similar for the treatment of myasthenia gravis (adults)

Summary